As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.
9 Analysts have issued a Adagio Therapeutics Inc forecast:
9 Analysts have issued a Adagio Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 50 50 |
333%
333%
|
|
| Gross Profit | 47 47 |
338%
338%
|
|
| EBITDA | -62 -62 |
74%
74%
|
|
| EBIT (Operating Income) EBIT | -62 -62 |
74%
74%
|
|
| Net Profit | -60 -60 |
73%
73%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
| Head office | United States |
| CEO | William Duke |
| Employees | 100 |
| Founded | 2020 |
| Website | invivyd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


